Cancer vaccines
Amal Therapeutics SA
Incorprated
03.09.2012Headquarters
GenèveSupport
Amal Therapeutics SA, a spin-off from the University of Geneva, is developing new cancer vaccines, using with a proprietary family of vectors.
News
Three startups in the spotlight (startupticker.ch)
AMAL Therapeutics’ keynote at the TOP 100: How 85 slides led to 2019’s biggest biotech exit in Europe (venturelab.swiss)
Recognition for Swiss innovation (startupticker.ch)
Female entrepreneurs in the spotlight (startupticker.ch)
TOP 100 Pitch Event With Credit Suisse Private Investors Club in Geneva (venturelab.swiss)
TOP 100 Swiss Startup Award 2019 - Switzerland’s 100 most-promising startups (venturelab.swiss)
Amal Therapeutics becomes a subsidiary of a German Pharma giant (startupticker.ch)
Amal Therapeutics Acquired by Boehringer Ingelheim for up to €425 Million (venturelab.swiss)
AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim (startupticker.ch)
Startup Champions Seed Night 2019: a thrilling evening for innovators in Switzerland (venturelab.swiss)
AMAL Therapeutics finalises CHF 33 million Series B round (startupticker.ch)
AMAL Therapeutics raises CHF 8.8 million in Series B round (startupticker.ch)
Top 100 Swiss startups have been revealed (startupticker.ch)
Amal Therapeutics raises CHF 3 million in a Series A financing round (startupticker.ch)
Amal Therapeutics receives CTI grant (startupticker.ch)
11 start-ups selected for Swiss Venture Day Romandie (startupticker.ch)
Amal Therapeutics and Oslo University Hospital announce research collaboration (startupticker.ch)
Start-ups selected for the 50th Swiss Venture Day (startupticker.ch)
Amal achieves proof of concept (startupticker.ch)
Nine hot start-ups, 400 visitors and Joe Jimenez (startupticker.ch)
Milestones news
